Pharmaceutical Technology
JULY 3, 2023
Pipeline developments within the obesity space have recently garnered interest following recent results published on Eli Lilly’s retatrutide.
Bio Pharma Dive
JULY 3, 2023
What is the GDPR and why does it matter to your life sciences company. iliomad Health Data can help you maintain GDPR compliance.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 3, 2023
2023 started with a buzz around ChatGPT, and more generally around the immense potential that generative AI (GenAI) holds.
Rethinking Clinical Trials
JULY 3, 2023
Pragmatic research is vulnerable to biases due to differences in data capture and access to care for different subsets of the population, which, if left unaddressed, can propagate inequities in health and the healthcare system. In a new article published online ahead of print in JAMIA , the NIH Pragmatic Trials Collaboratory’s Demonstration Project teams reflect on the health equity challenges encountered by their trials and share the specific strategies they used to mitigate sources of po
Pharmaceutical Technology
JULY 3, 2023
China has granted approval for Innovent Biologics and IASO Bio Fucaso for treating relapsed or refractory multiple myeloma (RRMM) in adults.
Bio Pharma Dive
JULY 3, 2023
As the new vice president of medical excellence with global consulting and software firm Acceleration Point, she’s excited to focus on the role of technology in advancing her industry.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
JULY 3, 2023
Project aims to boost the adoption of technology across London’s NHS and help patients manage conditions - News - PharmaTimes
Pharmaceutical Technology
JULY 3, 2023
The bioscience company has received $10m Series A financing from asset manager Mercia.
Outsourcing Pharma
JULY 3, 2023
George Freeman MP, minister of state at the new Department for Science, Innovation and Technology, has praised a decade of growth at Discovery Park, the leading science and innovation campus in Sandwich, Kent.
Pharmaceutical Technology
JULY 3, 2023
Baudax Bio has acquired all outstanding equity interests of biotechnology firm TeraImmune in a stock-for-stock deal.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Outsourcing Pharma
JULY 3, 2023
RAIR Health, an applied data and AI company focused on the extraction of clinical insights from real world data, has signed a non-exclusive data license agreement with Royal Cornwall Hospitals NHS Trust (RCH) focussed on the field of ophthalmology.
Pharmaceutical Technology
JULY 3, 2023
Chime Biologics, Leads Biolabs and BeiGene have entered a strategic partnership to expedite the development of a monoclonal antibody, LBL-007.
BioPharma Reporter
JULY 3, 2023
Donaldson, a provider of filtration products and solutions, has acquired Univercells Technologies, a producer of biomanufacturing solutions for cell and gene therapy research, development, and commercial manufacturing, to broaden its life sciences reach.
Pharmaceutical Technology
JULY 3, 2023
The NDA includes pivotal data from Phase III trials and a long-term extension, with one trial missing its primary endpoint.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Outsourcing Pharma
JULY 3, 2023
Kicking off a series of DIA Global interviews in Boston, OSP had the pleasure of speaking to Cal Collins, co-founder and CEO of OpenClinica - a company that wants to empower data managers, clinical researchers, and study participants.
Pharmaceutical Technology
JULY 3, 2023
The Humira biosimilar from Boehringer Ingelheim launches amidst a loss of exclusivity for AbbieVie’s blockbuster drug.
Pharma Times
JULY 3, 2023
The therapy becomes an option for moderate-to-severe plaque psoriasis in certain adults - News - PharmaTimes
Pharmaceutical Technology
JULY 3, 2023
In late June 2023, Celltrion (South Korea) withdrew its key anti-cancer biosimilar, Herzuma, from the UK market.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Cloudbyz
JULY 3, 2023
Sponsors or Contract Research Organizations (CROs) conduct several types of site visits at various stages of a clinical trial to ensure the quality and integrity of the data collected, compliance with protocols and regulatory requirements, and safety of the trial participants. These visits are an essential part of clinical trial management and oversight.
BioPharma Reporter
JULY 3, 2023
AstraZeneca has shared updated results from a recent phase 3 clinical trial of its Imfinzi (durvalumab) plus Imjudo (tremelimumab) treatment plan in certain patients with hepatocellular carcinoma (HCC), the most common type of liver cancer.
pharmaphorum
JULY 3, 2023
Australia first to prescribe MDMA and psilocybin for depression, PTSD Nicole.
Drug Patent Watch
JULY 3, 2023
[
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
pharmaphorum
JULY 3, 2023
AZ, Daiichi’s TROP2 drug hits the mark in lung cancer Phil.
Drug Patent Watch
JULY 3, 2023
LEVITRA (vardenafil hydrochloride) Bayer hlthcare Patent: 8,841,446 Expiration: Jul 3, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com… The post Drug Patent Expirations for the Week of July 2, 2023 appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
JULY 3, 2023
Don't hold back lab digital transformation Mike.
Drug Patent Watch
JULY 3, 2023
Annual Drug Patent Expirations for ADLARITY Adlarity is a drug marketed by Corium and is included in one NDA. It is available from one supplier. There are seven patents protecting… The post New patent for Corium drug ADLARITY appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Discovery World
JULY 3, 2023
It’s not easy being the new kid on the block. DDW’s Diana Spencer speaks to the CEOs of two drug discovery start-ups to find out how they have overcome the challenges of launching a new company in a competitive market. It’s a challenging time to launch a new company in the life sciences sector. High interest rates and other economic challenges, along with low investment, have made it very difficult for companies to raise funding.
Drug Patent Watch
JULY 3, 2023
Annual Drug Patent Expirations for CRESEMBA Cresemba is a drug marketed by Astellas and is included in two NDAs. It is available from one supplier. There are four patents protecting… The post New patent for Astellas drug CRESEMBA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery World
JULY 3, 2023
Janssen has announced positive results from the proof-of-concept Phase II UNITY trial for the treatment of pregnant individuals at high risk of early-onset severe (EOS) haemolytic disease of the foetus and newborn (HDFN). A statistically significant (54%) proportion of participants who received nipocalimab achieved the primary endpoint of a live birth at or after gestational age of 32 weeks without intrauterine transfusions (IUTs).
BioPharma Reporter
JULY 3, 2023
PrecisionLife, a techbio company driving precision medicine in complex chronic diseases, has announced a data access agreement with the University of Oxford to spearhead new treatments for endometriosis.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
299 
Let's personalize your content